Tests BrECADD chemotherapy in adults with advanced Hodgkin lymphoma and HIV
Tests BrECADD chemotherapy in adults with HIV and advanced Hodgkin lymphoma.
Plain-language title generated from the registry record
Registry title: Phase II Trial of BrECADD in HIV-Positive Patients With Advanced-Stage Classical Hodgkin Lymphoma
Key facts
- Where
- Berlin, Bremen, Cologne, Essen, Hamburg, Heidelberg, and Munich, GermanySee the 7 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT06919679, who can take part
Where in Germany
- Epimed Gesellschaft fuer epidemiologische und klinische Forschung in der Medizin mbHBerlin, GermanyNot yet recruiting
- Gesundheit Nord gGmbH Klinikverbund BremenBremen, GermanyNot yet recruiting
- Universitaetsklinikum Koeln AöRCologne, GermanyNot yet recruiting
- Universitaetsklinikum Essen (AoR)Essen, GermanyNot yet recruiting
- University Medical Center Hamburg-EppendorfHamburg, GermanyNot yet recruiting
- Universitaetsklinikum Heidelberg AöRHeidelberg, GermanyNot yet recruiting
- Rotkreuzklinikum Muenchen gGmbHMunich, GermanyNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Cologne
- Trial code
- NCT06919679EU 2025-521749-26-00
- Record updated
- 9 April 2025
- Original description
Participants receive chemotherapy with BrECADD in standard doses and cycle length. After the first two cycles, a restaging is performed by contrast-enhanced computed tomography (ceCT) and PET (PET/CT) in order to guide response-adapted continuation of therapy consisting of 4 or only 2 additional cycles of BrECADD in case of a PET-positive or -negative staging result, respectively. A second restaging will be performed after completion of chemotherapy. In patients with PET-positive residual disease, local irradiation followed by another restaging is recommended. ART should be continued during chemotherapy.Read full original descriptionShow less
Phase II Trial of BrECADD in HIV-Positive Patients With Advanced-Stage Classical Hodgkin Lymphoma
Participants receive chemotherapy with BrECADD in standard doses and cycle length. After the first two cycles, a restaging is performed by contrast-enhanced computed tomography (ceCT) and PET (PET/CT) in order to guide response-adapted continuation of therapy consisting of 4 or only 2 additional cycles of BrECADD in case of a PET-positive or -negative staging result, respectively. A second restaging will be performed after completion of chemotherapy. In patients with PET-positive residual disease, local irradiation followed by another restaging is recommended. ART should be continued during chemotherapy.
Inclusion: Histologically confirmed first diagnosis of cHL; Advanced-stage disease: stage IIB with large mediastinal mass and/or extranodal lesions or stage III or IV; No previous treatment for HL with the exception of steroid prephase; Confirmed HIV infection with CD4 counts ≥ 150/μL at registration or > 250/μL at any time within 8 months prior to HL diagnosis; Continuation of antiretroviral treatment (ART) / Initiation of ART in patients who are ART-naive; Age: 18-60 years.
Exclusion: Multi-drug resistant HIV infection or concurrent AIDS-defining conditions; Previous malignancy during last 5 years or active malignancy, prior chemotherapy or radiotherapy which precludes protocol treatment; Nodular lymphocyte-predominant Hodgkin lymphoma or composite lymphoma; Pregnancy or breastfeeding.